Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NCInfluenza and other respiratory viruses

RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study.

  • Keren Armoni Domany1,2
  • Inbal Golan-Tripto3,4
  • Nitzan Burrack4,5
  • Kamal Masarweh6,7
  • Michal Gur6,7
  • Mika Rochman2,8
  • Moria Be'er2,8
  • Dario Prais2,9
  • Meirav Mor2,10
  • Moran Weinberger Opek11
  • Elias Nasrallah12,13
  • Orli Megged14
6 more authors
  • Rachel Shatzman Steuerman2,15,16
  • Michal Stein2,15
  • Zohar Steinberg7,17
  • Shereen Shehadeh7,18
  • Aharona Glatman-Freedman2,19
  • Diana Tasher2,20
20 affiliations
  1. 1Pediatric Pulmonology Unit, Wolfson Medical Center, Holon, Israel.
  2. 2Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  3. 3Pediatric Pulmonary Unit, Soroka University Medical Center, Beer-Sheva, Israel.
  4. 4Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  5. 5Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel.
  6. 6Pediatric Pulmonary Institute and CF Center, The Ruth Rappaport Children's Hospital, Haifa, Israel.
  7. 7Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
  8. 8Pediatric Pulmonology Unit, Dana-Dwek Children's Hospital, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
  9. 9Pulmonary Institute, Schneider Children's Medical Center, Petah Tikva, Israel.
  10. 10Emergency Medicine and Infectious Control Unit, Schneider Children's Medical Centre, Petah Tikva, Israel.
  11. 11Department of Pediatrics, Samson Assuta Ashdod University Hospital, Ashdod, Israel.
  12. 12Saint Vincent De Paul- French Hospital, Nazareth, Israel.
  13. 13Azrieli Faculty of Medicine, Bar-ilan University, Safed, Israel.
  14. 14Shaare Zedek Medical Center (affiliated with Hebrew University, Hadassah School of Medicine), Jerusalem, Israel.
  15. 15Pediatric Infectious Disease Unit, Sheba Medical Center, Tel-Hashomer, Israel.
  16. 16Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel.
  17. 17Department of Pediatrics, Emek Medical Center, Afula, Israel.
  18. 18Department of Pediatrics, Carmel Medical Center, Haifa, Israel.
  19. 19Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel.
  20. 20Pediatric Infectious disease unit, E. Wolfson Medical center, Holon, Israel.
Read full textPDFDOICite

Abstract

Background

Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalization, yet data on children hospitalized with RSV in their second year of life are limited.Objective

To compare clinical characteristics and management practices of children hospitalized with RSV during their second versus first year of life.Methods

This retrospective multicenter study included children aged 0-23 months hospitalized with RSV infection across 11 medical centers between 2017 and 2021. We compared demographics, outcomes (length of stay [LOS] > 3 days, and pediatric intensive care unit [PICU] admission), and systemic corticosteroid and antibiotic use between the second and first years of life, adjusting for prematurity, comorbidities, and the COVID-19 pandemic.Results

Among 6260 children hospitalized with laboratory-confirmed RSV infection, 1321 (21%) were hospitalized during their second year of life. Compared with first-year admissions, second-year patients had higher rates of prematurity (18.0% vs. 13.4%) and comorbidities (6.3% vs. 2.6%) (both p < 0.001). They more frequently received corticosteroids (53.5% vs. 23.2%) and antibiotics (63.4% vs. 45.9%) (both p < 0.001) and had lower PICU admission rates (4.6% vs. 7.0%; p < 0 0.001) and similar rates of prolonged LOS (35.0% vs. 35.6%; p = 0.64). In adjusted analyses, second-year hospitalization was associated with increased corticosteroid use (adjusted odds ratio [aOR], 4.28; 95% CI, 3.67-4.99) and antibiotic use (aOR, 2.09; 95% CI, 1.80-2.43), and lower odds of PICU admission (aOR, 0.56; 95% CI, 0.40-0.79).Conclusions

RSV hospitalization in the second year of life carries a significant burden, with higher antibiotic and corticosteroid use despite lower PICU rates and similar LOS. These findings highlight the need for better characterization of this age group to optimize future immunoprophylaxis strategies.

Related

  1. Survival Patterns and Prognostic Factors Among Children Hospitalized with Severe Malaria in Mbujimayi, Democratic Republic of the Congo: A Multicenter Cohort Study.
    Rodrick Tshiunza Banza, Simon Ilunga Kandolo, Michel Kabamba Nzaji
    Journal of multidisciplinary healthcarePeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMCPMC
  2. Vitamin D Deficiency Among Hospitalized Children with Community-Acquired Pneumonia: Prevalence and Association with Disease Severity.
    Babak Abdinia, Azar Dastranji, Yousef Abedifard +1
    Pediatric health, medicine and therapeuticsPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Factors associated with discharge on higher respiratory support for children with tracheostomy hospitalized with bacterial tracheostomy‐associated infections: A prospective, multicenter cohort study
    Krystal S. Jin, Naoko Kono, Jonathan D. Cogen +11
    Journal of Hospital MedicinePeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  4. Assessment of the appropriateness of stress ulcer prophylaxis practice among hospitalized patients across Lebanese hospitals: A multicenter prospective study
    Khouloud Housary, Carole Dib, Rania Itani
    PLOS OnePeer-reviewedCC BY 4.0Epidemiology & public healthInfectious diseasePLOS
  5. Epidemiological characteristics and in-hospital burden of infectious mononucleosis among hospitalized children in China, 2021–2023
    Yuxin Shao, Xinyu Wang, Ziyi Su +4
    Virologica SinicaPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{domany2026disease,
  title = {{RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study.}},
  author = {Keren Armoni Domany and Inbal Golan-Tripto and Nitzan Burrack and Kamal Masarweh and Michal Gur and Mika Rochman and Moria Be'er and Dario Prais and Meirav Mor and Moran Weinberger Opek and Elias Nasrallah and Orli Megged and Rachel Shatzman Steuerman and Michal Stein and Zohar Steinberg and Shereen Shehadeh and Aharona Glatman-Freedman and Diana Tasher},
  journal = {Influenza and other respiratory viruses},
  year = {2026},
  month = oct,
  doi = {10.1111/irv.70338},
  url = {https://europepmc.org/article/MED/42952123},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study.
AU  - Keren Armoni Domany
AU  - Inbal Golan-Tripto
AU  - Nitzan Burrack
AU  - Kamal Masarweh
AU  - Michal Gur
AU  - Mika Rochman
AU  - Moria Be'er
AU  - Dario Prais
AU  - Meirav Mor
AU  - Moran Weinberger Opek
AU  - Elias Nasrallah
AU  - Orli Megged
AU  - Rachel Shatzman Steuerman
AU  - Michal Stein
AU  - Zohar Steinberg
AU  - Shereen Shehadeh
AU  - Aharona Glatman-Freedman
AU  - Diana Tasher
PY  - 2026
DA  - 2026/10/28
JO  - Influenza and other respiratory viruses
DO  - 10.1111/irv.70338
UR  - https://europepmc.org/article/MED/42952123
AB  - Background  Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalization, yet data on children hospitalized with RSV in their second year of life are limited.Objective  To compare clinical characteristics and management practices of children hospitalized with RSV during their second versus first year of life.Methods  This retrospective multicenter study included children aged 0-23 months hospitalized with RSV infection across 11 medical centers between 2017 and 2021. We compared demographics, outcomes (length of stay [LOS] > 3 days, and pediatric intensive care unit [PICU] admission), and systemic corticosteroid and antibiotic use between the second and first years of life, adjusting for prematurity, comorbidities, and the COVID-19 pandemic.Results  Among 6260 children hospitalized with laboratory-confirmed RSV infection, 1321 (21%) were hospitalized during their second year of life. Compared with first-year admissions, second-year patients had higher rates of prematurity (18.0% vs. 13.4%) and comorbidities (6.3% vs. 2.6%) (both p < 0.001). They more frequently received corticosteroids (53.5% vs. 23.2%) and antibiotics (63.4% vs. 45.9%) (both p < 0.001) and had lower PICU admission rates (4.6% vs. 7.0%; p < 0 0.001) and similar rates of prolonged LOS (35.0% vs. 35.6%; p = 0.64). In adjusted analyses, second-year hospitalization was associated with increased corticosteroid use (adjusted odds ratio [aOR], 4.28; 95% CI, 3.67-4.99) and antibiotic use (aOR, 2.09; 95% CI, 1.80-2.43), and lower odds of PICU admission (aOR, 0.56; 95% CI, 0.40-0.79).Conclusions  RSV hospitalization in the second year of life carries a significant burden, with higher antibiotic and corticosteroid use despite lower PICU rates and similar LOS. These findings highlight the need for better characterization of this age group to optimize future immunoprophylaxis strategies.
SN  - 1750-2640
SN  - 1750-2659
ER  -